Author

Celia Bolumburu

Institution: Johnson & Johnson (United States)

Observed institution: Johnson & Johnson (United States)

OpenAlex ID: A5115009462

Observational retrospective study of the treatment of Waldenström’s macroglobulinemia with ibrutinib in routine clinical practice in Spain

2025 · Carlos Fernández de Larrea, Javier Loscertales, et al. · Therapeutic Advances in Hematology

Ibromics: A Real-World Study of Clinical and Biological Parameters in Patients with Chronic Lymphocytic Leukemia (CLL) Treated in First Line with Single Agent Ibrutinib

2024 · Cecilia Muñoz-Calleja, José Ángel Hernández-Rivas, et al. · Blood

Works count: 2

Citation count:

H-index:

I10-index: